Varant Arzoumanian, MD
Hematology & Oncology · Fort Smith, ARNPI 1790904027
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 457 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations.
Across 457 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AstraZeneca$804
- Novartis$598
- Gilead$588
- Merck$573
- Daiichi Sankyo Inc.$385
- plus $4K from 33 others
What the payments were for
- Food & beverage$6,76190%
- Education$72810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 77 | $1,032 |
| AstraZeneca | 44 | $804 |
| Novartis | 32 | $598 |
| Gilead(2 entities) | 37 | $588 |
| Merck | 37 | $573 |
| Daiichi Sankyo Inc. | 19 | $385 |
| Rigel Pharmaceuticals, Inc. | 24 | $382 |
| Johnson & Johnson(2 entities) | 22 | $325 |
| AbbVie | 15 | $304 |
| GSK | 19 | $292 |
| Myovant Sciences Inc. | 14 | $216 |
| Astellas Pharma US Inc | 13 | $213 |
| Eisai Inc. | 11 | $198 |
| Amgen | 12 | $181 |
| Bristol Myers Squibb | 7 | $129 |
| Lilly USA, LLC | 8 | $122 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $117 |
| EMD Serono, Inc. | 7 | $117 |
| Array Biopharma Inc | 8 | $112 |
| Puma Biotechnology, Inc. | 6 | $103 |
| Genentech USA, Inc. | 5 | $84 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| Seagen Inc. | 4 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Ipsen Biopharmaceuticals, Inc | 3 | $50 |
| Boehringer Ingelheim | 3 | $46 |
| Foundation Medicine, Inc. | 3 | $44 |
| Beigene USA, Inc. | 3 | $42 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Epizyme, Inc. | 2 | $34 |
| Sanofi | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Menarini Silicon Biosystems, Inc. | 1 | $20 |
| Acceleron Pharma, Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
How this compares
$7,489 in reported general payments places this provider in the 65th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 49 | $940,908 |
| Lenalidomide | 62 | $744,258 |
| RevlimidLenalidomide | 41 | $651,691 |
| InlytaAxitinib | 29 | $626,721 |
| XtandiEnzalutamide | 43 | $546,037 |
| PromactaEltrombopag Olamine | 30 | $505,353 |
| BosulifBosutinib | 25 | $439,525 |
| CalquenceAcalabrutinib Maleate | 27 | $421,125 |
| PomalystPomalidomide | 18 | $411,751 |
| KisqaliRibociclib Succinate | 24 | $381,719 |
| CabometyxCabozantinib S-Malate | 11 | $313,006 |
| VenclextaVenetoclax | 41 | $306,367 |
| LynparzaOlaparib | 18 | $299,519 |
| VerzenioAbemaciclib | 18 | $276,069 |
| IbrancePalbociclib | 17 | $265,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna, Promacta, Kisqali, Tafinlar, Mekinist | $598 | $2,229,582129 claims |
| PfizerInlyta, Bosulif, Ibrance, Eliquis | $1,032 | $1,451,138251 claims |
| AstraZenecaCalquence, Lynparza | $804 | $720,64445 claims |
| Bristol Myers SquibbRevlimid | $129 | $651,69141 claims |
| Astellas Pharma US IncXtandi | $213 | $546,03743 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $26 | $411,75118 claims |
| Array Biopharma IncBraftovi, Mektovi | $112 | $353,59922 claims |
| AbbVieVenclexta, Linzess | $304 | $313,69955 claims |
| Lilly USA, LLCVerzenio | $122 | $276,06918 claims |
| Genentech USA, Inc.Alecensa | $84 | $202,16813 claims |
| Johnson & JohnsonXarelto | $325 | $82,754127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Fort Smith
- Isam Abdel-KarimFort Smith$199K
- Humdum DurraniFort Smith$54K
- Narender GorukantiFort Smith$20K
- Daniel MackeyFort Smith$6K
- Aswanth ReddyFort Smith$5K
- John WellsFort Smith$5K
- Daniel MilesFort Smith$2K
- Suma Sri ChennapragadaFort Smith$2K
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.